Molecular phenotyping of ~100,000 coding variants across Mendelian disease genes
- Institution
- DANA-FARBER CANCER INST, MA
- Principal investigator
- Marc Vidal
- Funding
- $1.8M
- Duration
- 2021–2026
Moonbase score
Still being scored
Abstract
Abstract The last four decades have produced an enormous catalog of human genomic variants which has the potential to revolutionize human genetics. Among the variants identified in the human “variome” so far, some appear benign, i.e. they don’t seem to confer any particular phenotype, a significant proportion are associated or potentially associated with one or more genetically inherited disorders, but an even greater percentage of observed human variants, 99% of missense variants, remain uninterpreted or annotated as variants of unknown significance (VUSs). To translate this huge amount of genetic information into general principles underlying genotype-phenotype relationships as well as molecular mechanisms responsible for the development of inherited disease, there is an urgent need for large-scale, systematic, high throughput “functional characterization” projects such as those envisioned within the new “Impact of Genomic Variation on Function” (IGVF) Consortium proposed by NHGRI. Although most monogenic Mendelian disorders are individually rare, when combined these diseases affect 20 million Americans. The ClinVar database describes within 3,671 Mendelian disease genes over 260,000 missense variants classified as pathogenic, benign, or VUSs. We currently lack strong and comprehensive evidence to systematically analyze coding variants across the spectrum of human Mendelian diseases. We propose to functionally characterize ~100,000 variants across most of the known Mendelian disease- associated genes by comparing wild-type, or “reference”, gene products and their corresponding variants for a rich array of fundamental protein properties and phenotypic impacts, including protein stability (expression), subcellular localization, cell viability, cell morphology, and the ability to mediate macromolecular interactions with protein partners. Our Variant Characterization Across the Mendelian Proteome (VarChAMP) Center will generate a searchable and widely available catalog of these variant effects via the IGVF Data and Administrative Coordinating Centers (DACCs), and assist in the “Predictive Modeling Projects” to carry out variant effect predictive modeling using this data. In addition to providing a rich source of functional information on tens of thousands of genomic variants in the next five years, all of our concepts, technologies and resources generated during this project are exportable and will be shared to enable others, both inside and outside the IGVF consortium, to leverage our approach in their own studies and expand the catalog.
LOADING MOONBASE SCORE
Questions for DANA-FARBER CANCER INST
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Dana-Farber Cancer InstNot yet scored
Selective disruption of histone deacetylase complexes using protein interaction modulators
Marc Vidal · $680K · 2022–2027
- NIH · Dana-Farber Cancer InstNot yet scored
Generating a full-length reference transcriptome for human protein-coding genes
David E. Hill · $640K · 2022–2027
- NIH · Dana-Farber Cancer Inst51
HIV-1 Preintegration Trafficking and Nuclear Localization
Alan N. Engelman · $1.2M · 2003–2027